What is clinical trial NCT04772079 studying?

NCT04772079 is a Phase 3 clinical trial evaluating Deucravacitinib for Plaque Psoriasis. The trial is sponsored by Bristol-Myers Squibb and is currently recruiting.

What phase is the NCT04772079 clinical trial?

NCT04772079 is a Phase 3 clinical trial. Phase 3 trials are pivotal studies required before FDA approval, typically enrolling hundreds to thousands of participants to prove efficacy and safety.

Is NCT04772079 still recruiting participants?

The current enrollment status of NCT04772079 is: Recruiting. The trial is actively enrolling — check ClinicalTrials.gov for eligibility criteria.

Who is the sponsor of clinical trial NCT04772079?

NCT04772079 is sponsored by Bristol-Myers Squibb (BMY). BiotechSign currently grades the sponsor a C (51/100) based on its composite pipeline strength and catalyst outlook.

Home›Trial›NCT04772079

NCT04772079Phase 3Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

Study Summary

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.

Conditions

Plaque Psoriasis

Interventions / Drugs

Deucravacitinib Placebo matching deucravacitinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment153 participants

Primary Completion2029-01-01

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-10-14

What This Trial Means for Biotech Investors

Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Primary completion: 2029-01-01

Enrolled: 153 participants

Sponsor Catalyst Profile

Bristol-Myers Squibb (BMY) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BMY Full Pipeline →All Companies →

Other Trials from Bristol-Myers Squibb

NCT07215962Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non…NCT05489705A Prospective Registry Study to Assess Real-world Patient Characteristics, Treat…NCT07063342A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC …(PHASE1)NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agi…(PHASE3)NCT06003426A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part…(PHASE3)

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.